港股創新藥ETF升超3%，公募基金對醫藥持倉持續提升
格隆匯2月1日丨港股醫藥迎來大反彈，匯添富基金港股通創新藥ETF、銀華基金港股創新藥ETF、平安基金港股醫藥ETF、廣發基金港股創新藥ETF升幅超3%。
醫藥股下跌，公募基金對醫藥持倉持續提升，2023年末全部公募基金持有醫藥股佔比13.59%，環比增長1.1%。
從公募基金持倉家數來看，公募基金數量前五的分別是：恒瑞醫藥(703家)、邁瑞醫療(552家)、藥明康德(388家)、智飛生物(382家)、人福醫藥(177家)；基金數量增加前五支股票分別是：恒瑞醫藥(+158家)、智飛生物(+158家)、邁瑞醫療(+109家)、新產業(+53家)、奕鋭科技(+49家)。
從公募基金持倉佔比情況來看，1）持倉佔流通股比例前五分別為：惠泰醫療(31.4%)、百洋醫藥(25.5%)、九典制藥(25.1%)、悦康藥業(24.9%)、邁威生物-U(21.6%)；2）持倉佔總股本前五分別為：惠泰醫療(21.2%)、金域醫學(21%)、愛博醫療(16.4%)、藥明康德(16.3%)、健之佳(16%)。
從公募基金持倉總市值來看，持倉總市值排名前五分別是：邁瑞醫療(430.1億元)、恒瑞醫藥(417.5億元)、藥明康德(351.7億元)、智飛生物(176.2億元)、愛爾眼科（158.9億元)；變動情況來看，基金持倉市值增加前五分別為：智飛生物(+61.3億元)、邁瑞醫療(+60.8億元)、恒瑞醫藥(+59.8億元)、新產業(+43億元)、天壇生物(+19億元)。
對於醫藥板塊，銀華基金李曉星、張萍認為，創新藥進入收穫期，我們對2024年的醫藥板塊繼續保持樂觀。配置上，我們會繼續以“創新”為主線，主要倉位配置有國際競爭力的創新藥、醫療器械；另外我們看到，消費醫療板塊具備預期低、估值低、股價位置低的優勢，我們也將底部佈局一些業績增速快、估值合理的醫療服務和其他消費醫療。
中歐基金葛蘭指出，展望2024年一季度，全球投融資環境有望在加息週期後逐步恢復，國內政策端或保持平穩，行業對合規化影響的認知會更加清晰。儘管不同子板塊間的基數有所不同，但我們認為醫藥行業整體仍將保持穩健增長的趨勢，優秀企業長期增長的驅動力並未出現重大變化。我們預期醫療行業供需格局會進一步改善。供給端，創新仍是重要驅動力。後續成熟靶點的適應症逐步拓展，新靶點的概念持續驗證中，都為創新藥企提供了廣闊的成長空間。療法方面，基因編輯、細胞治療等前沿療法不斷有突破性進展，後續商業化前景值得關注。需求端，居民對消費性醫療及醫療服務的需求也在快速增長。2023年減重、阿爾茨海默症等領域的研發突破成為行業關注焦點，一部分應用市場逐步打開，但依然有大量臨牀需求未得到充分滿足，包括用藥的便捷性、舒適性等也有較大的臨牀價值。伴隨人口週期與結構演變，人類疾病譜不斷變化，對應的國內乃至全球市場需求總量依然巨大，創新藥及創新器械都有着廣闊的成長空間。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
